Literature DB >> 18552856

A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease.

Xiaogang Li1, Brenda S Magenheimer, Sheng Xia, Teri Johnson, Darren P Wallace, James P Calvet, Rong Li.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is caused by heterozygous mutations in either PKD1 or PKD2, genes that encode polycystin-1 and polycystin-2, respectively. We show here that tumor necrosis factor-alpha (TNF-alpha), an inflammatory cytokine present in the cystic fluid of humans with ADPKD, disrupts the localization of polycystin-2 to the plasma membrane and primary cilia through a scaffold protein, FIP2, which is induced by TNF-alpha. Treatment of mouse embryonic kidney organ cultures with TNF-alpha resulted in formation of cysts, and this effect was exacerbated in the Pkd2(+/-) kidneys. TNF-alpha also stimulated cyst formation in vivo in Pkd2(+/-) mice. In contrast, treatment of Pkd2(+/-) mice with the TNF-alpha inhibitor etanercept prevented cyst formation. These data reveal a pathway connecting TNF-alpha signaling, polycystins and cystogenesis, the activation of which may reduce functional polycystin-2 below a critical threshold, precipitating the ADPKD cellular phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552856      PMCID: PMC3359869          DOI: 10.1038/nm1783

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  28 in total

1.  FIP-2, a coiled-coil protein, links Huntingtin to Rab8 and modulates cellular morphogenesis.

Authors:  K Hattula; J Peränen
Journal:  Curr Biol       Date:  2000 Dec 14-28       Impact factor: 10.834

Review 2.  Self-perpetuating states in signal transduction: positive feedback, double-negative feedback and bistability.

Authors:  James E Ferrell
Journal:  Curr Opin Cell Biol       Date:  2002-04       Impact factor: 8.382

Review 3.  Genetics and pathogenesis of polycystic kidney disease.

Authors:  Peter Igarashi; Stefan Somlo
Journal:  J Am Soc Nephrol       Date:  2002-09       Impact factor: 10.121

Review 4.  Polycystic kidney disease.

Authors:  Patricia D Wilson
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

5.  A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease.

Authors:  K M Dell; R Nemo; W E Sweeney; J I Levin; P Frost; E D Avner
Journal:  Kidney Int       Date:  2001-10       Impact factor: 10.612

6.  Tumor necrosis factor-alpha inhibits renin gene expression.

Authors:  Vladimir Todorov; Markus Müller; Frank Schweda; Armin Kurtz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-11       Impact factor: 3.619

Review 7.  Autosomal dominant polycystic kidney disease: modification of disease progression.

Authors:  D J Peters; M H Breuning
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

Review 8.  Biological functions of tumor necrosis factor cytokines and their receptors.

Authors:  Klaus Pfeffer
Journal:  Cytokine Growth Factor Rev       Date:  2003 Jun-Aug       Impact factor: 7.638

9.  Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells.

Authors:  Surya M Nauli; Francis J Alenghat; Ying Luo; Eric Williams; Peter Vassilev; Xiaogang Li; Andrew E H Elia; Weining Lu; Edward M Brown; Stephen J Quinn; Donald E Ingber; Jing Zhou
Journal:  Nat Genet       Date:  2003-01-06       Impact factor: 38.330

10.  IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.

Authors:  Dung-Fang Lee; Hsu-Ping Kuo; Chun-Te Chen; Jung-Mao Hsu; Chao-Kai Chou; Yongkun Wei; Hui-Lung Sun; Long-Yuan Li; Bo Ping; Wei-Chien Huang; Xianghuo He; Jen-Yu Hung; Chien-Chen Lai; Qingqing Ding; Jen-Liang Su; Jer-Yen Yang; Aysegul A Sahin; Gabriel N Hortobagyi; Fuu-Jen Tsai; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Cell       Date:  2007-08-10       Impact factor: 41.582

View more
  62 in total

1.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Inhibition of the P2X7 receptor reduces cystogenesis in PKD.

Authors:  Ming-Yang Chang; Jenn-Kan Lu; Ya-Chung Tian; Yung-Chang Chen; Cheng-Chieh Hung; Yi-Hui Huang; Yau-Hung Chen; Mai-Szu Wu; Chih-Wei Yang; Yi-Chuan Cheng
Journal:  J Am Soc Nephrol       Date:  2011-06-02       Impact factor: 10.121

3.  Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.

Authors:  Lucy X Fan; Xia Zhou; William E Sweeney; Darren P Wallace; Ellis D Avner; Jared J Grantham; Xiaogang Li
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

Review 4.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 5.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 6.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

7.  Degradome of soluble ADAM10 and ADAM17 metalloproteases.

Authors:  Franka Scharfenberg; Andreas Helbig; Martin Sammel; Julia Benzel; Uwe Schlomann; Florian Peters; Rielana Wichert; Maximilian Bettendorff; Dirk Schmidt-Arras; Stefan Rose-John; Catherine Moali; Stefan F Lichtenthaler; Claus U Pietrzik; Jörg W Bartsch; Andreas Tholey; Christoph Becker-Pauly
Journal:  Cell Mol Life Sci       Date:  2019-06-17       Impact factor: 9.261

Review 8.  Treatment strategies and clinical trial design in ADPKD.

Authors:  Vicente E Torres
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

9.  Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group.

Authors:  Melanie S Joy; Debbie S Gipson; Leslie Powell; Jacqueline MacHardy; J Charles Jennette; Suzanne Vento; Cynthia Pan; Virginia Savin; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Am J Kidney Dis       Date:  2009-11-22       Impact factor: 8.860

10.  Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease.

Authors:  Xia Zhou; Lucy X Fan; William E Sweeney; John M Denu; Ellis D Avner; Xiaogang Li
Journal:  J Clin Invest       Date:  2013-06-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.